Bibliography

Export 7 results:
Filters: Author is Korbling,M.  [Clear All Filters]
2002
Anderlini P, Chan FA, Champlin RE, Korbling M, Strom SS. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: No evidence of increased risk of leukemia development. Bone Marrow Transplant. 2002;30:661-663.
Esmaeli B, Ahmadi MA, Kim S, Onan H, Korbling M, Anderlini P. Marginal keratitis associated with administration of filgrastim and sargramostim in a healthy peripheral blood progenitor cell donor. Cornea. 2002;21(6):621-2.
2001
Korbling M, Giralt S, Khouri I, Mirza N, Donato M, Anderlini P, et al. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. Journal of Clinical Apheresis. 2001;16(2):82-7.
1999
Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ, et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion. 1999;39(6):555-60.
1996
Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B, et al. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.[Erratum appears in Transfusion 1997 Jan;37(1):109]. Transfusion. 1996;36(7):590-5.
Korbling M, Anderlini P, Durett A, Maadani F, Bojko P, Seong D, et al. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplantation. 1996;18(6):1073-9.
Anderlini P, Przepiorka D, Seong D, Champlin R, Korbling M. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. British Journal of Haematology. 1996;94(1):155-8.